D.E. Shaw & Co
AVBP icon

D.E. Shaw & Co’s ArriVent BioPharma AVBP Stock Holding History

D.E. Shaw & Co’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.51M Buy
368,795
+135,471
+58% +$3.06M 0.01% 1773
2025
Q4 		$4.69M Buy
+233,324
New +$4.86M ﹤0.01% 2359
2024
Q4 		– Sell
-8,775
Closed -$206K – 4963
2024
Q3 		$206K Buy
+8,775
New +$199K ﹤0.01% 4143

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co's AVBP Position: Q1 2026 in Review

D.E. Shaw & Co increased its ArriVent BioPharma (AVBP) stake by 58% in Q1 2026, buying an estimated $3.06M and bringing the position to 368,795 shares worth $8.51M. The position accounts for 0.01% of the portfolio, ranked #1773.

D.E. Shaw & Co first reported a position in AVBP in Q3 2024 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • D.E. Shaw & Co held 368,795 shares of ArriVent BioPharma worth $8.51M as of Q1 2026.
  • D.E. Shaw & Co bought 135,471 ArriVent BioPharma shares in Q1 2026, an estimated $3.06M.
  • ArriVent BioPharma made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1773 holding.
  • D.E. Shaw & Co first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.